Cite
Troelsgaard A, Pitcher A, Granados D, et al. The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France. Value Health. 2014;17(7):A346-7doi: 10.1016/j.jval.2014.08.707.
Troelsgaard, A., Pitcher, A., Granados, D., Hemels, M., & Lloyd, A. (2014). The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A346-7. https://doi.org/10.1016/j.jval.2014.08.707
Troelsgaard, A, et al. "The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A346-7. doi: https://doi.org/10.1016/j.jval.2014.08.707
Troelsgaard A, Pitcher A, Granados D, Hemels M, Lloyd A. The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France. Value Health. 2014 Nov;17(7):A346-7. doi: 10.1016/j.jval.2014.08.707. Epub 2014 Oct 26. PMID: 27200657.
Copy
Download .nbib
